...
首页> 外文期刊>Memo - Magazine of European medical oncology >Evidence-based follow-up in colorectal cancer-quo vadis?
【24h】

Evidence-based follow-up in colorectal cancer-quo vadis?

机译:结直肠癌癌症 - QUO VADIS的循证随访?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Colorectal cancer is the third most common and the third most lethal cancer disease in the western world. As most patients undergo treatment with curative intent at initial diagnosis, postoperative surveillance protocols have been established with the primary aim to detect possible disease recurrence in an early resectable stage. Various international guidelines recommend an intensive surveillance protocol over a 5-year time period. These guidelines are based on the reported significant benefit regarding overall patient survival, and on the observation that 90% of recurrences occur within the first 5 years following resection. Surveillance protocols include regular clinical examinations, measurement of the carcinoembryonic antigen, computed tomography scans and regular endoscopies. While there is plenty of evidence regarding the scheduling of endoscopies, the frequency of carcinoembryonic antigen measurements and computed tomography scans has been ever since under debate. The benefit of intensive compared to low frequency surveillance protocols regarding disease-specific survival has never been shown. Moreover, recent meta-analyses and randomized controlled trials challenge current guidelines. Intensive carcinoembryonic antigen assessment and computed tomography scan follow-up protocols seem to fail in generating better overall and disease-specific survival in colorectal cancer patients compared to less intensive surveillance strategies. This change over the last few decades parallels the treatment evolution of colorectal cancer from a primarily surgical to a multidisciplinary task. Instead of advocating a reduction of the follow-up intensity, these findings should stimulate the colorectal oncology field to move from a one-fits-all to a patient-centered surveillance.
机译:结肠直肠癌是西方世界第三个最常见和第三次致命的癌症疾病。由于大多数患者在初步诊断时用治疗意图进行治疗,已经建立了术后监测方案,以初级目的在早期可移植阶段检测可能的疾病复发。各种国际指南建议在5年期间建议一项强化监测议定书。这些指南基于报告的总体患者存活率的显着益处,并且在分解后的前5岁内发生90%的复发。监测方案包括常规临床检查,测量癌丙烯抗原,计算断层扫描扫描和常规内窥镜。虽然有大量有关内窥镜调度的证据,但自辩论以来,癌症胚胎抗原测量和计算机断层扫描扫描的频率是有关的。与疾病特异性生存期的低频监测协议相比,密集的益处从未显示过。此外,最近的Meta分析和随机对照试验挑战了当前指南。密集的癌胚抗原评估和计算的断层扫描随访协议似乎在结肠直肠癌患者中产生更好的整体和疾病特异性生存率,而相比,相比较少的监测策略。过去几十年来的这种变化使整数癌的治疗演变与主要手术到多学科任务。这些发现应该刺激患者以患者为中心的监视,而不是提倡减少后续强度,这些结果应刺激结肠直肠肿瘤学领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号